Previous Pause Next
Home >> News Center >> Enterprise & Industry >>
Enterprise & Industry
Denovo Partners with ALS Nonprofit to ID Biomarkers PDF Print E-mail
Friday, 10 May 2013 23:18
SAN DIEGO, May 10, 2013 – The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo’s technology to identify potential responder groups for drugs being studied in ALS patients. This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.
Read more...
 
Abbott Developing CDx for Merck Investigational Cancer Drug PDF Print E-mail
Wednesday, 07 March 2012 15:09

http://www-static.abbott.com/_cache_-1272670386-1009685431-334528742-7599018981469783648/static/images/Abt_wBL_2C_Blue3.gifAbbott said today it will provide a companion diagnostic for an investigational cancer therapy being developed by Merck.

Under the terms of the deal, Abbott will use its fluorescence in situ hybridization technology to develop a test to identify deletions of the TP53 gene in cancer patients. The assay will be evaluated in clinical trials for its ability to select the most appropriate patients for Merck's therapy.

Read more...
 
Lundbeck makes $200M down payment in blockbuster CNS drug pact with Otsuka PDF Print E-mail
Saturday, 12 November 2011 06:08

Danish drugmaker Lundbeck and Japanese drug giant Otsuka have joined forces for a pact that makes the two companies major partners in the global market for drugs against diseases of the central nervous system. Both companies now have a lot riding on developmental CNS drugs in the deal as each company's best-selling drugs face generic competition in the coming years.

Read more...
 
Quertle And Ariadne Announce Technology Partnership PDF Print E-mail
Saturday, 05 June 2010 13:07
Quertle, LLC and Ariadne announce a technology partnership to support new applications in biomedical text and knowledge search. Ariadne will provide both proprietary technology and technical resources to Quertle.
Read more...
 
GlaxoSmithKline Savings Plan May Hit XenoPort, Inc. Partnership PDF Print E-mail
Monday, 08 February 2010 15:24

The future of a partnership between XenoPort Inc. and GlaxoSmithKline PLC appeared to be in doubt Thursday after Glaxo said it may end research on pain treatments.

GlaxoSmithKline, one of the world's largest drugmakers, said its neuroscience researchers will focus on inflammatory and degenerative diseases and may stop research into depression and pain drugs.

Read more...
 
Archemix Corporation and Dicerna Pharmaceuticals to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics PDF Print E-mail
Wednesday, 22 July 2009 00:00
Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, and Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNA (DsiRNA) molecules, announced today that the two companies have entered into an agreement to collaborate on aptamer-DsiRNA therapeutics that leverage both the intracellular delivery capabilities of Archemix’s aptamers, and the potent gene silencing of Dicerna’s DsiRNA molecules. Both companies are making an investment of resources to develop the aptamer-DsiRNA therapeutics, and will work collaboratively on the R&D activities. The agreement includes an option for Dicerna to obtain exclusive rights to further develop and commercialize aptamer-DsiRNA therapeutics generated during the collaboration. Additional terms of the agreement were not disclosed.
Read more...
 
Skyepharma PLC (SKYE): Settlement of Formoterol Certihaler(TM) Termination with Novartis AG PDF Print E-mail
Monday, 20 July 2009 00:00
SkyePharma PLC (LSE: SKP) today announces that it has reached agreement with Novartis Pharma AG (“Novartis”) and with a subcontractor on immediate termination of the contracts relating to formoterol Certihaler™. The agreements follow the decision not to proceed with US commercialisation of formoterol Certihaler™ as announced in December 2008.
Read more...
 
Proteome, Millipore in Deal for Alzheimer's Study Products PDF Print E-mail
Monday, 06 July 2009 09:40
http://www.proteome.co.uk/images/splash/company_logo.gifBritish pharmaceuticals and biotechnology company Proteome Sciences Plc (PRM.L) and Millipore Corp (MIL.N) have signed an exclusive license agreement to develop new products to study Alzheimer's disease, the companies said in a statement.
Read more...
 
Paladin Labs Inc. (CC:PLB) Announces the Closing of its Partnership for the Commercialization of Voclosporin PDF Print E-mail
Friday, 19 June 2009 10:38

http://www.paladin-labs.com/images/logo.gifPaladin Labs Inc., a leading Canadian specialty pharmaceutical company, today announced the closing of its strategic partnership with Isotechnika Pharma Inc. (TSX: ISA) for the commercialization of voclosporin, Isotechnika's next-generation calcineurin inhibitor, in Canada, Mexico, Central & South America, Israel and South Africa.

Read more...
 
BioSeek and Merck Serono Extend 2008 Agreement - Compound Profiling Collaboration Continues into 2012 PDF Print E-mail
Wednesday, 10 June 2009 10:09

BioSeek, Inc., a pioneer in the application of predictive human biology to drug discovery, announced today that it has signed a new, three-year collaboration agreement with Merck KGaA, Darmstadt, Germany, acting for its division Merck Serono, extending and expanding the companies’ previous 2008 compound profiling agreement. Under the research plan, BioSeek will continue to use its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.

Read more...
 
Qiagen, Bio-X Center Establish Translational Medicine Lab in Shanghai PDF Print E-mail
Thursday, 22 March 2012 07:18

NEW YORK (GenomeWeb News) – Qiagen today announced it and the Bio-X Center of Shanghai Jiao Tong University will jointly create a translational medicine laboratory in Shanghai.

Read more...
 
Abbott Laboratories Spends $400 Million on Reata Pharmaceuticals, Inc. Development Deal PDF Print E-mail
Tuesday, 13 December 2011 06:00
IRVING, Texas, Dec. 12, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership between the two companies announced in September 2010 in which Reata granted to Abbott exclusive rights to develop and commercialize its lead AIM compound, bardoxolone methyl, outside of the United States, excluding certain Asian markets.
Read more...
 
UCSF-Pfizer partnership yields projects aimed at clinical trials PDF Print E-mail
Friday, 28 October 2011 00:37

An 11-month-old partnership between UCSF and Pfizer, Inc., aimed at rapidly moving new therapies into human clinical trials, has selected its first projects for funding and joint development. Teams from the University and Pfizer will work together on experimental therapies developed by the UCSF scientists with a goal of testing them in people with five hard-to-treat, often deadly conditions, including lung and prostate cancer.

Read more...
 
Biomoda and Amigenics Announce Collaboration PDF Print E-mail
Saturday, 06 March 2010 15:08
Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) and Advanced Medical Imaging and Genetics (Amigenics) (www.amigenics.com), an innovative medical clinic specializing in prevention and early detection of disease, announced their intent to collaborate on a variety of projects to advance technology for the early detection of lung and other cancer.
Read more...
 
Genentech, Roche Pare Partnerships PDF Print E-mail
Wednesday, 23 December 2009 16:38

Genentech and parent company Roche canceled three drug-development partnerships deals this month, raising fears that the Bay Area’s largest biotech is trimming back its traditionally wide range of lucrative research collaborations with other firms.

Read more...
 
Avidas Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement PDF Print E-mail
Wednesday, 22 July 2009 00:00

Avidas Pharmaceuticals and LaRon Pharma Inc. today announced that they have entered into an agreement for LaRon to co-promote Avidas' key prescription-only convenience kits, Avidoxy(TM) DK defence kit and Scalacort(TM) DK defence kit. Under the terms of the agreement, LaRon will provide sales support focused on primary care and internal medicine physicians in the United States, while Avidas will continue its sales force specialty focus in dermatology. Avidas will also maintain full marketing rights for each of the products. Specific financial terms of the deal were not disclosed.

Read more...
 
Targacept to Receive $10M as AstraZeneca Scales Up CNS Disorder Partnership PDF Print E-mail
Wednesday, 08 July 2009 10:12

http://www.targacept.com/img/img_targ_bldg.jpgAstraZeneca has expanded and amended its agreement with Targacept related to cognitive diseases, triggering a $10 million fee. AstraZeneca says that it will add attention deficit/hyperactivity disorder (ADHD) to the AZD3480 program, which already includes schizophrenia and Alzheimer’s. Additionally, the firm will develop AZD1446 for Alzheimer’s disease.

Read more...
 
GE Healthcare, Geron Partner on Stem Cell-Based Assays PDF Print E-mail
Tuesday, 30 June 2009 10:25

http://www.gehealthcare.com/usen/gehc/blue_7455/images/monogram.gifGE Healthcare and Geron jointly announced today that they will collaborate on developing and selling human embryonic stem cell-based assays for drug discovery, development, and toxicity screening.

Read more...
 
Illumina Partners with DTC Genomics Firms to Offer Whole Genome Sequencing for $48K PDF Print E-mail
Thursday, 11 June 2009 07:38

BOSTON — Illumina and four direct-to-consumer genomics firms — 23andMe, Knome, Navigenics, and Decode Genetics — have joined forces to bring whole genome sequencing analysis of genetic risk information to customers.

Read more...
 
Bayhill Therapeutics, Inc. Enters Exclusive, Worldwide Collaboration with Genentech, Inc. (DNA) for BHT-3021 in Type 1 Diabetes; Deal Could Potentially Exceed $350M PDF Print E-mail
Wednesday, 10 June 2009 09:40

http://www.bayhilltx.com/art/sml_logo.gifBayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential http://www.gene.com/gene/img/globalhdr/global-logo.gifcommercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).

Read more...
 
<< Start < Prev 1 2 Next > End >>

Page 1 of 2